← Back to Search
A Phase II Trial Of Low-dose Gemcitabine In A Prolonged Infusion And Cisplatin For Malignant Pleural Mesothelioma
V. Kovač, M. Zwitter, M. Rajer, A. Marin, A. Debeljak, U. Smrdel, M. Vrankar
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
After a favorable experience with gemcitabine at a low dose in a prolonged infusion in combination with cisplatin for advanced non-small-cell lung cancer, here, we present the results from a phase II trial for patients with malignant pleural mesothelioma. Eligible patients had biopsy-proven malignant pleural mesothelioma, were chemo-naive, Eastern Cooperative Oncology Group performance status 0–2, had normal hematopoietic liver and renal function, and gave informed consent. Treatment consisted of gemcitabine 250 mg/m2 in a 6-h infusion on days 1 and 8 and cisplatin at 75 mg/m2 on day 2 of a 3-week cycle for four cycles, followed by two additional cycles without cisplatin. Seventy-eight patients (58 men, 20 women; age 33–82 years, median 58) were recruited into the trial. The histologic types were as follows: epitheloid 56 (71.8%); four sarcomatoid (5.1%); mixed 15 (19.2%); and mesothelioma, three not otherwise specified (3.8%). Grades 3–4 toxicity included two (2.6%) patients with anemia, 18 (23.1%) with neutropenia, and one with nausea/vomiting. Reversible thrombocytosis with platelets over 1000–109/l was recorded in 10 (12.8%) patients and grade 2 alopecia in 60 (76.9%). Four (5.1%) patients showed a complete response and 35 (44.9%) showed a partial response with a response rate of 39/78 (50%). Minimal response or stable disease was seen in 35 (44.9%), whereas only four (5.1%) patients progressed during treatment. Most patients reported symptomatic improvement with a higher or a stable quality of life score in 70 (89.7%) cases. The median progression-free survival was 8.0 months (confidence interval 6.9–9.0). The median overall survival was 17.0 months (confidence interval 14.7–19.2). One-year, two-year, and three-year survival rates were 67.3, 32.7, and 19.8%, respectively. Epitheloid histological type was the only statistically significant favorable prognostic factor for progression-free survival and overall survival. Because of the acceptable toxicity, remarkable activity, and reasonable cost, this treatment should be further explored.
This paper references
J. Espinosa Arranz (1994)
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.
H. Anderson (1996)
Cancer Registry of Republic of Slovenia. Cancer incidence in Slovenia
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma
A. Favaretto (2003)
Malignant Pleural Mesothelioma: A Population-Based Study of Survival
M. Milano (2010)
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma.
G. Ceresoli (2011)
A Practical Guide of the Southwest Oncology Group to Measure Malignant Pleural Mesothelioma Tumors by RECIST and Modified RECIST Criteria
A. Tsao (2011)
Analysis of latency time and its determinants in asbestos related malignant mesothelioma cases of the Italian register.
A. Marinaccio (2007)
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.
S. Mikulski (2002)
Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors
J. Maurel (2001)
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
N. Touroutoglou (1998)
domestic and environmental mesothelioma risks in the British population: a case-control study
C Rake (2009)
Optimal designs for phase II clinical trials
R. Simon (1989)
Cisplatin and Gemcitabine in Malignant Pleural Mesothelioma: A Phase II Study
B. Castagneto (2005)
Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma
J. Sørensen (2008)
The Mesothelioma and Radical Surgery Randomized Controlled Trial: The MARS Feasibility Study
T. Treasure (2009)
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
M. Ralli (2009)
Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study
G. Hillerdal (2008)
Phase II trial of low - dose gemcitabine in prolonged infusion and cisplatin for advanced non - small
JP Xiong (2008)
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
S. Kalmadi (2008)
Primary chemotherapy with low-dose prolonged infusion gemcitabine and cisplatin in patients with bladder cancer: a Phase II trial.
H. Khaled (2008)
Chemotherapy Induced Pathologic Complete Response in Malignant Pleural Mesothelioma: A Review and Case Report
C. Bech (2010)
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
C. Lee (2009)
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II Clinical Trial
M. Zwitter (2009)
followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma
MT Milano (2009)
Pleural mesothelioma. In: UICC International Union Against Cancer, editor. TNM classification of malignant tumours
LH Sobin (2009)
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
Optimal two-stage designs for phase II clinical trials.
R. Simon (1989)
Treatment of advanced NSCLC (Stage IIIB and IV) with low dose gemcitabine and carboplatin
P. M. Parikh (2005)
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
A. DE GASPERIS (1950)
Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV.
S. Aversa (1999)
Pharmacokinetic evaluation of gemcitabine and 2',2'-difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors.
L. Cattel (2006)
Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial
M. Zwitter (2010)
Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
Brad E Wilcox (2009)
Achievement of Complete Remission in Refractory Hodgkin's Disease with Prolonged Infusion of Gemcitabine
O. Sezer (2004)
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.
L. Krug (2009)
Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels
C. F. Pollera (2004)
Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
B. Castagneto (2008)
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
J. Abbruzzese (1991)
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Occupational, domestic and environmental mesothelioma risks in the British population: a case–control study
C. Rake (2009)
Saturation of 2′, 2′-difluorodeoxycytidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine
R. Grunewald (2004)
Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy.
M. Socinski (2004)
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
F. Fossella (1997)
Emerging drugs for mesothelioma
G. Scagliotti (2007)
Phase II Trial of a 24-Hour Infusion of Gemcitabine in Previously Untreated Patients with Advanced Pancreatic Adenocarcinoma
F. Eckel (2003)
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
Systemic Treatments for Mesothelioma: Standard and Novel
H. Kindler (2008)
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
A. Santoro (2008)
Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
K. Akrivakis (1999)
Phase II trial of a 24-h infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma
F Eckel (2003)
Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
J. Xiong (2008)
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
A Phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors
R. Brand (2004)
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas
E. Spaeth-Schwalbe (2000)
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study
P. Schmid (2005)
Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study.
N. Katirtzoglou (2010)
This paper is referenced by
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
A. Scherpereel (2020)
Independent Clinical Research May Alleviate Disparities in Cancer Treatment
Matjaz Zwitter (2016)
Prolonged low-dose infusion for gemcitabine: a systematic review
Dehua Zhao (2019)
De-hua Zhao (2019)
Release of growth factors after mechanical and chemical pleurodesis for treatment of malignant pleural effusion: a randomized control study
A. Hojski (2015)
Asbestos-Related Pleural Diseases: The Role of Gene-Environment Interactions
V. Dolžan (2019)
Induction gemcitabine in standard dose or prolonged low-dose with cisplatin followed by concurrent radiochemotherapy in locally advanced non-small cell lung cancer: a randomized phase II clinical trial
M. Vrankar (2014)
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma
O. Arrieta (2014)
Polymorphisms in translesion polymerase genes influence treatment outcome in malignant mesothelioma.
K. Goričar (2014)
DNA Repair Polymorphisms and Treatment Outcomes of Patients with Malignant Mesothelioma Treated with Gemcitabine-Platinum Combination Chemotherapy
N. Erčulj (2012)
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a comparative study of pharmacokinetic models and correlation with mRECIST criteria
Martina Vivoda Tomšič (2019)
Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma
K. Goričar (2014)
Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma
V. Kovač (2015)
Low-dose gemcitabine in long infusion: when less is more.
M. Zwitter (2012)
The hedgehog pathway on malignant mesothelioma
C. Lim (2015)
Serum Survivin Levels and Outcome of Chemotherapy in Patients with Malignant Mesothelioma
K. Goričar (2015)
Cytotoxics and Anti-Angiogenics: Metronomic Therapies
Andreas Pircher (2017)
Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: Population-based survey of 444 patients
V. Kovač (2012)
Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma
K. Goričar (2017)
Semirigid thoracoscopy: an effective method for diagnosing pleural malignancies
A. Rozman (2014)
Treating Malignant Pleural Mesothelioma : an update on the situation at the dawn of 2014
Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials.
A. Mansfield (2014)
ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma.
I. Opitz (2020)
Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials
Man-Tang Qiu (2012)
The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
C. C. Boons (2013)
What can independent research for mesothelioma achieve to treat this orphan disease?
A. Guazzelli (2019)
Computed tomography and Modified RECIST criteria for assessment of response in malignant pleural mesothelioma
A. Marin (2013)